Choose HA†
Prescribing Information   |  OAKneePainRelief.com
7.1.5-header-iStock-898328226

Videos

Contact a Rep

Knee Injection Videos

Capture

HA Injection Demonstration Video

This video demonstrates the injection technique using the superolateral portal, one of several acceptable techniques. The superolateral approach is the most accurate technique based on several clinical studies. See the accompanying literature review video for more information on injection technique accuracy.

Watch video
injectionvideo-thumbnail

HA Injection Techniques Literature Review

This video presents evidence from a literature review of the most accurate injection techniques for intra-articular HA injections in patients with knee osteoarthritis, including the benefits of using ultrasound guidance.

Watch video
Supartz videos1

SUPARTZ FX: Injection Portal Overview

Watch video
Supartz videos2

SUPARTZ FX: Inferior Lateral Injection Technique

Watch video
Supartz videos3

SUPARTZ FX: Inferior Medial Injection Technique

Watch video
Supartz videos4

SUPARTZ FX: Superior Lateral Injection Technique

Watch video
Supartz videos5

SUPARTZ FX: Superior Medial Injection Technique

Watch video
Supartz videos6

SUPARTZ FX: Inferior Medial Injection Technique

Watch video

DUROLANE, GELSYN-3 and SUPARTZ FX are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g., acetaminophen. Risks include general knee pain and pain at the injection site.

View Use and Important Safety Information at: DUROLANE.com, GELSYN3.com, and SUPARTZFX.COM

Summary of Indications for Use:
DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.